BAT with carboplatin for TP53-altered prostate cancer
Official title: Targeting TP53-altered castration-resistant prostate cancer with bipolar androgen therapy (BAT) plus carboplatin.
Funded at Mayo Clinic Rochester · NIH-11334070 · Data updated 2026-11-12
This project tests a combination treatment using high-dose testosterone swings plus carboplatin for men whose prostate cancer has changed TP53 status and progressed after standard therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 18, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $417,554 |
| NIH project number | 1P50CA298941-01A1 |
| Project ID | NIH-11334070 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with advanced or metastatic castration-resistant prostate cancer and TP53-related alterations, who have progressed on standard therapies.
✕Less likely to help
Patients without TP53-altered tumors or those not eligible for BAT or carboplatin may not benefit.
What this research studies
Prostate cancer can become resistant to usual hormone therapies. This grant explores bipolar androgen therapy, which uses alternating high and low testosterone levels alongside carboplatin to target cancer cells, with the goal of improving outcomes in patients whose tumors show TP53 alterations. The study is anchored at Mayo Clinic in Rochester and led by Emmanuel S. Antonarakis, MD. If successful, it could offer a new option for men facing advanced, treatment-resistant disease. The approach combines a biologically active hormonal strategy with chemotherapy in a precise, disease-focused way.
Why it matters
Potential benefit: If successful, patients may experience better responses or delayed progression in advanced prostate cancer with TP53 alterations.
How similar studies have gone: Early clinical data suggest potential activity of BAT in resistant disease, but this specific combination and genetic context are novel and exploratory.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Antonarakis, Emmanuel S. — Mayo Clinic Rochester
- Study coordinator: Antonarakis, Emmanuel S.
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.